MetaCap

Pfizer (PFE) vs Vertex Pharmaceuticals (VRTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Vertex Pharmaceuticals (VRTX) has outperformed Pfizer (PFE) over the past year, gaining 20.7% versus a gain of 9.4%. Over five years, VRTX leads with a +180.5% price change compared with -49.3% for PFE. Pfizer is the larger company by market cap ($156.18 billion vs $130.58 billion), about 1.2 times the size, while Vertex Pharmaceuticals is growing revenue faster (+8.9% vs -1.6%).

On valuation, Pfizer trades at a lower forward P/E (9.3x vs 25.9x for Vertex Pharmaceuticals). Pfizer pays a dividend yielding 7.85%, while Vertex Pharmaceuticals does not currently pay one. Vertex Pharmaceuticals converts more of its revenue into profit, with a net margin of 32.9% versus 12.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

PFE+9.42%VRTX+20.68%
+33%+13%-7%
Nov 21, 20251 yearNov 20, 2026
PFE-46.06%VRTX+181.62%
+219%+74%-70%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

PFE versus VRTX key metrics
MetricPFEVRTX
Share price$27.40$515.02
Market cap$156.18B$130.58B
1-day change-0.51%-1.08%
YTD return+10.04%+13.60%
1-year return+9.42%+20.68%
5-year return-49.26%+180.53%
P/E ratio (TTM)39.1433.14
Forward P/E9.2825.86
EPS (TTM)$0.70$15.54
Dividend yield7.85%0.00%
Annual dividend$2.15$0.00
Revenue (latest FY)$62.58B$12.00B
Revenue growth (YoY)-1.65%+8.90%
Net income (latest FY)$7.77B$3.95B
Gross margin74.33%86.24%
Operating margin—34.77%
Net margin12.42%32.94%
52-week high$31.44$568.67
52-week low$23.62$412.27
Distance from 52-week high-12.85%-9.43%
Analyst consensusbuybuy
Avg. price target upside+10.29%+15.60%
Average volume33.52M1.25M
Shares outstanding5.70B253.54M
Employees75,0006,400
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • VRTX has outperformed PFE by 11.3 percentage points over the past year.
  • Pfizer offers a meaningfully higher dividend yield (7.85% vs 0.00%).
  • Vertex Pharmaceuticals is more profitable, keeping 32.9 cents of every revenue dollar as net income versus 12.4 cents for Pfizer.
  • Vertex Pharmaceuticals grew revenue faster in its latest fiscal year (+8.90% vs -1.65%).

About Pfizer

PFE stock →

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally.

Health Care · Biotechnology: Pharmaceutical Preparations · 75,000 employees

About Vertex Pharmaceuticals

VRTX stock →

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain.

Health Care · Biotechnology: Pharmaceutical Preparations · 6,400 employees

PFE vs VRTX FAQ

Which is bigger, Pfizer or Vertex Pharmaceuticals?

Pfizer (PFE) is larger, with a market capitalization of $156.18B compared with $130.58B for Vertex Pharmaceuticals (VRTX).

Which stock has performed better over the past year, PFE or VRTX?

VRTX returned +20.68% over the past 12 months, compared with +9.42% for PFE (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, PFE or VRTX?

VRTX has the lower trailing P/E at 33.1, versus 39.1 for PFE. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Which pays a higher dividend, Pfizer or Vertex Pharmaceuticals?

Pfizer pays a dividend yielding 7.85%, while Vertex Pharmaceuticals does not currently pay a regular dividend.

Are Pfizer and Vertex Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons